Apricus Biosciences (APRI) Tops Q2 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. TMUS
7. SPY
8. CVS
9. UNH
10. DAL

Go back to Apricus Biosciences (APRI) Tops Q2 EPS by 3c

Apricus Biosciences Provides Corporate Update and Second Quarter Financial Results

August 4, 2016 4:02 PM EDT

Strategic Focus on Growing Global Vitaros® Revenue and Achieving Profitability in 2017Apricus Granted Type B Meeting with FDA to Discuss the Vitaros® U.S. NDA Re-SubmissionConference Call / Webcast Today, Thursday, August 4, 2016 at 4:30 p.m. ET

SAN DIEGO, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the second quarter of 2016 and provided a corporate update on its priorities for 2016.

In the second quarter, we... More